- Home
- EKSO vs BIAF Comparison
EKSO vs BIAF Comparison
Compare EKSO & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EKSO
- BIAF
- Stock Information
- Founded
- EKSO 2005
- BIAF 2014
- Country
- EKSO United States
- BIAF United States
- Employees
- EKSO N/A
- BIAF N/A
- Industry
- EKSO Medical/Dental Instruments
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- EKSO Health Care
- BIAF Health Care
- Exchange
- EKSO Nasdaq
- BIAF Nasdaq
- Market Cap
- EKSO 13.4M
- BIAF 11.1M
- IPO Year
- EKSO N/A
- BIAF 2022
- Fundamental
- Price
- EKSO $0.54
- BIAF $0.73
- Analyst Decision
- EKSO Strong Buy
- BIAF Strong Buy
- Analyst Count
- EKSO 2
- BIAF 1
- Target Price
- EKSO $5.50
- BIAF $6.00
- AVG Volume (30 Days)
- EKSO 2.9M
- BIAF 300.4K
- Earning Date
- EKSO 03-03-2025
- BIAF 03-31-2025
- Dividend Yield
- EKSO N/A
- BIAF N/A
- EPS Growth
- EKSO N/A
- BIAF N/A
- EPS
- EKSO N/A
- BIAF N/A
- Revenue
- EKSO $17,682,000.00
- BIAF $9,367,785.00
- Revenue This Year
- EKSO N/A
- BIAF $285.51
- Revenue Next Year
- EKSO $32.74
- BIAF $20.05
- P/E Ratio
- EKSO N/A
- BIAF N/A
- Revenue Growth
- EKSO 4.12
- BIAF 2813.87
- 52 Week Low
- EKSO $0.47
- BIAF $0.57
- 52 Week High
- EKSO $2.32
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- EKSO 36.46
- BIAF 37.84
- Support Level
- EKSO $0.47
- BIAF $0.69
- Resistance Level
- EKSO $0.67
- BIAF $0.85
- Average True Range (ATR)
- EKSO 0.06
- BIAF 0.08
- MACD
- EKSO -0.01
- BIAF 0.01
- Stochastic Oscillator
- EKSO 22.90
- BIAF 50.00
About EKSO Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are EksoHealth and EksoWorks. All of the company's operations are held in the United States. The EksoHealth segment which derives majority revenue designs, engineers, manufactures and sells exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The regions company operates in are the Americas, EMEA, and APAC.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.